Drug Trial Radar · NCT02949895
Study of BMS-986012 in Subjects With Small Cell Lung Caner
Last checked: Nov 19, 2026Latest source record: Aug 12, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
7
Actual
Start
Nov 29, 2016
Primary completion
Aug 29, 2017
Study completion Aug 29, 2017
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Oct 31, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A study to evaluate safety and tolerability of BMS-986012 in patients with small cell lung cancer
Conditions
- Small Cell Lung Cancer
Interventions
BMS-986012Drug
CisplatinDrug
EtoposideDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with adverse events (AEs)Time frame: Up to 2 years
- Number of participants with serious adverse events (SAEs )Time frame: Up to 2 years
- Number of Discontinuations due to AEsTime frame: Up to 2 years
- Number of Deaths due to AEsTime frame: Up to 2 years
- Number of participants with laboratory toxicity grade shift from baselineTime frame: Up to 2 years
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Local Institution
Takatsuki-shi, Osaka, Japan
Local Institution
Chuo-ku, Tokyo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.